SUPREFACT

This brand name is authorized in Austria, Brazil, Canada, Spain, Netherlands, Singapore, United Kingdom, South Africa

Active ingredients

The drug SUPREFACT contains one active pharmaceutical ingredient (API):

1 Buserelin UNII 13U86G7YSP - BUSERELIN ACETATE

Buserelin is a synthetic peptide. It is a superactive analogue of natural gonadotrophin releasing hormone (gonadorelin, LHRH or GNRH). After an initial stimulation of gonadotrophin release, it down-regulates the hypothalanic-pituitary-gonadal axis. Read about Buserelin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
SUPREFACT Nasal spray	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC
SUPREFACT Injection	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L02AE01	Buserelin	L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02A Hormones and related agents → L02AE Gonadotropin releasing hormone analogues
Discover more medicines within L02AE01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 502811901171315
Country: CA	Health Products and Food Branch	Identifier(s): 02225158, 02225166, 02228955, 02240749
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 57011, 60980, 62477
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 39293, 42572
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 22756, 50997
Country: SG	Health Sciences Authority	Identifier(s): 04362P
Country: ZA	Health Products Regulatory Authority	Identifier(s): 32/21.10/0345, V/21.10/170